Repligen Corporation (RGEN) Shares Bought by Teachers Advisors LLC

Teachers Advisors LLC lifted its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 6.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,096 shares of the biotechnology company’s stock after acquiring an additional 4,015 shares during the quarter. Teachers Advisors LLC owned 0.18% of Repligen Corporation worth $2,573,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of RGEN. BlackRock Inc. increased its position in shares of Repligen Corporation by 143,196.5% during the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock valued at $164,187,000 after acquiring an additional 4,661,047 shares during the last quarter. TimesSquare Capital Management LLC increased its position in shares of Repligen Corporation by 19.8% during the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after acquiring an additional 390,545 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Repligen Corporation by 49.8% during the second quarter. William Blair Investment Management LLC now owns 1,058,976 shares of the biotechnology company’s stock valued at $43,884,000 after acquiring an additional 352,045 shares during the last quarter. Stephens Investment Management Group LLC increased its position in shares of Repligen Corporation by 25.2% during the second quarter. Stephens Investment Management Group LLC now owns 857,714 shares of the biotechnology company’s stock valued at $35,544,000 after acquiring an additional 172,796 shares during the last quarter. Finally, Marshall Wace North America L.P. increased its position in shares of Repligen Corporation by 60.9% during the second quarter. Marshall Wace North America L.P. now owns 414,146 shares of the biotechnology company’s stock valued at $16,980,000 after acquiring an additional 156,828 shares during the last quarter. 96.45% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/10/20/repligen-corporation-rgen-shares-bought-by-teachers-advisors-llc.html.

Repligen Corporation (NASDAQ:RGEN) opened at 37.11 on Friday. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 72.62 and a beta of 1.18. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The stock has a 50 day moving average price of $40.62 and a 200-day moving average price of $39.74.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. Repligen Corporation’s revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.16 EPS. Equities analysts predict that Repligen Corporation will post $0.59 EPS for the current fiscal year.

A number of brokerages recently commented on RGEN. Jefferies Group LLC reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen Corporation in a research report on Thursday. Zacks Investment Research lowered Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. First Analysis raised Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Stephens reaffirmed an “overweight” rating and issued a $50.00 price target on shares of Repligen Corporation in a report on Tuesday, September 26th. Finally, TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Repligen Corporation presently has a consensus rating of “Buy” and a consensus target price of $45.40.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply